Insulin-related lipohypertrophy remains a prevalent and underrecognized complication in patients with diabetes. A study published in the Journal of Diabetes Investigation developed a simple diagnostic model to identify high-risk individuals using three easily obtainable clinical variables.

The cross-sectional study enrolled 395 insulin-treated patients at a tertiary hospital in Tianjin, China, between December 2021 and November 2022. Ultrasound assessment revealed lipohypertrophy in 89.6% of patients, with 91.5% of lesions located in the abdomen. Logistic regression identified self-injection, duration of insulin therapy, and incorrect rotation of injection sites as significant predictors.

Based on these factors, a diagnostic nomogram was constructed and validated, demonstrating strong accuracy, good calibration, and practical clinical use. The tool enables clinicians to recognize lipohypertrophy risk early, reinforcing the importance of proper injection technique and site rotation in daily diabetes management.